Two pharmacies quote the same compounded formulation at very different prices, and the cheaper one cannot legally supply you the way you want to use it. That is the 503A versus 503B distinction, and it drives both what you are allowed to keep on the shelf and what you pay.
The difference in one line
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| Compounds against | A prescription for an identified patient | Batch production, may be office stock |
| Office stock | Generally no | Yes — this is the point |
| Registration | State board of pharmacy | Registers with FDA as an outsourcing facility |
| Manufacturing standard | USP standards | Subject to CGMP requirements |
| Typical unit economics | Higher per unit, no batch minimum | Lower per unit at volume |
| Best for | Individualized dosing, small volume | Predictable, repeatable menu items |
The practical consequence: if you want vials on hand to draw from as patients walk in, you are generally talking about a 503B outsourcing facility. If each preparation is made for a named patient against their prescription, that is 503A territory.
Where operators get this wrong
- Using 503A product as office stock. Ordering patient-specific compounds and holding them for whoever comes in next. Common, and the wrong side of the line.
- Assuming compounded means FDA-approved. It does not. Compounded preparations are not FDA-approved drugs, and marketing them as equivalent is a claims problem.
- No documented relationship. Sourcing through a rep with no agreement, no license verification, and no record of what was ordered.
- Ignoring supply-chain requirements. There are federal traceability obligations around prescription drug distribution, and enforcement attention in this area has increased.
- Buying on price alone. The cheapest quote sometimes reflects a facility you would not want named alongside your brand.
What actually moves your cost
Price is not only a function of negotiation. It moves with:
- Volume and predictability. Committed, forecastable volume prices differently from sporadic orders.
- Formulation complexity. Fewer components and standard concentrations cost less than bespoke blends.
- Menu discipline. Six variants of the same peptide at five concentrations fragments your volume across SKUs and forfeits leverage.
- Shipping and cold chain. Temperature-controlled products carry real logistics cost — and real risk if handled badly.
- Aggregation. A single location negotiates as a single location. A group negotiates as a group.
That last point is where most independent operators lose money. It is not that they negotiated badly; it is that they negotiated alone.
How to vet a pharmacy partner
- Confirm licensure in your state, not just theirs — non-resident pharmacy registration is a real requirement.
- For a 503B, confirm current FDA outsourcing facility registration.
- Ask for inspection history and any warning letters, and read them.
- Ask how they handle recalls and how you would be notified.
- Ask about beyond-use dating and how they support cold chain in transit.
- Get the relationship in writing, including what happens on a back-order.
A pharmacy that finds these questions annoying is telling you something useful.
Clinical decisions come first
Sourcing is a supply question sitting on top of a clinical one. A licensed provider still has to evaluate the patient and decide the treatment is appropriate before anything is dispensed or administered. Better pricing on a product nobody was properly evaluated for is not a saving.
What MDside brings
MDside maintains 503A and 503B pharmacy relationships, along with lab and supply relationships, and makes them available to the practices we support. Operators get access to sourcing they would struggle to negotiate individually, with the licensure and documentation confirmed rather than assumed.
Alongside that sits the clinical layer that makes the sourcing usable: the professional entity, licensed providers, evaluation workflow, and prescribing infrastructure. See what is included, or read about bringing lab draws in-house.
Frequently asked questions
What is the difference between 503A and 503B?
A 503A pharmacy compounds against a prescription for an identified patient. A 503B outsourcing facility registers with FDA, is subject to CGMP requirements, and can produce batches that may be supplied as office stock.
Can I keep compounded vials as office stock?
Generally that points to a 503B outsourcing facility. Holding patient-specific 503A preparations as general stock is a common and avoidable error.
Are compounded medications FDA-approved?
No. Compounded preparations are permitted to be prescribed under federal law but are not FDA-approved products, and should not be marketed as though they were.
How do I lower my compounding costs?
Consolidate your menu, commit to forecastable volume, and negotiate as part of a larger group rather than as a single location. Menu discipline usually beats haggling.
Does my pharmacy need to be licensed in my state?
Typically yes — non-resident pharmacy registration requirements apply in most states. Verify it rather than take it on faith.
General information about compounded medication sourcing, not legal advice. Pharmacy licensure, compounding rules, and supply-chain obligations vary by state and change over time. Confirm with healthcare counsel and verify any pharmacy’s current registration directly.